We provide the latest news
from the world of economics and finance
(RTTNews) - Lisata Therapeutics, Inc. (LSTA) announced on Tuesday that it has received an orphan drug designation from the FDA for LSTA1, the company's primary product candidate, to treat osteosarcoma, a rare form of bone cancer that can occur in young individuals.
The orphan drug designation is set to allow a seven-year exclusive marketing period after approval, along with exemption from user fees and eligibility for tax credits for applicable clinical trials.
LSTA1 has previously obtained orphan drug designation for pancreatic cancer in the U.S. and Europe, as well as for glioblastoma multiforme and osteosarcoma in the U.S. Moreover, it secured a Fast Track designation for pancreatic cancer and, on March 21, 2024, a Rare Pediatric Disease designation for osteosarcoma from the FDA.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.